Isolation of an anti-angiogenic substance from Agaricus blazei Murill: Its antitumor and antimetastatic actions

Cancer Science

Volumn 95, Issue 9, 2004, Pages 758-764

  Kimura, Yoshiyuki ^a   Kido, Tadashi ^c   Takaku, Takeshi ^b   Sumiyoshi, Maho ^a   Baba, Kimiye ^c  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; MATRIGEL; PYROGLUTAMATE SODIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

AGARICUS BLAZEI; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; IMMUNOMODULATION; IMMUNOREACTIVITY; LEWIS CARCINOMA; LUNG METASTASIS; LYMPHOCYTE COUNT; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN LYMPHOCYTE; T LYMPHOCYTE; TUMOR CELL;

ADMINISTRATION, ORAL; AGARICUS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; COLLAGEN; DRUG COMBINATIONS; FEMALE; KILLER CELLS, NATURAL; LAMININ; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; PYRROLIDONECARBOXYLIC ACID; SPLEEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 5044220447     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03258.x     Document Type: Article

References (21)

1. Ishihara T. Polysaccharide of Agaricus blazei Murill. In: Tanimura A, editor. Handbook of active substances in plant resources. 2nd ed. Tokyo: Science Forum; 1999. p. 348-50 (in Japanese).
2. Nikkei Biotechnology & Business 2004; 3: 44-5 (in Japanese).
3. Mizuno T, Inagaki R, Kano T, Hagiwara T, Nakamura T, Itoh T, Shimura K, Sumiya T, Asakura A. Antitumor activity and some properties of water-soluble polyaccharides from "Himematsutake," the fruiting body of Agaricus blazei Murill. Agric Biol Chem 1990; 54: 2889-96.
4. Itoh H, Ito H, Amano H, Bode T. Inhibitory action of (1-6)-β-glucan-protein complex (FIII 020b) isolated from Agaricus blazei Murill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn J Pharmacol 1994; 66: 265-71.
5. Kawagishi H, Kano T, Inagaki R, Mizuno T, Shimura K, Itoh H, Hagiwara T, Nakamura T. Formolysis of a potent antitumor (1-6)-β-glucan-protein complex from Agaricus blazei fruiting bodies and antitumor activity of the resulting products. Carbohydr Polym 1990; 12: 393-403.
6. Bulimia Y, Suzuki T, Shim K, Koori H, Moriguchi K, Nakashima H, Matsumoto Y, Takahara S, Ebina T, Katakura R. Selective tumoridical effect of soluble proteoglucan extracted from the Basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother 1998; 46: 147-59.
7. Takaku T, Kimura Y, Okuda T. Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr 2001; 131: 1409-13.
8. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Paulyt RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 1992; 67: 519-28.
9. Glaves D, Weiss L. Initial arrest patterns of circulating cancer cells: effects of host sensitization and anticoagulatrion. In: Weiss L, ed. Fundamental aspects of metastasis. Amsterdam: North-Holland; 1976. 263-73.
10. Blood CH, Letter BR. Tumor interactions with the vascular, angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
11. Feraral N. Missing link in angiogenesis. Nature 1995; 376: 467.
12. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
13. O'Reilly MS, Boem T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
14. Pross HF, Lotzova E. Role of natural killer cells in cancer. Nat Immun 1993; 12: 279-92.
15. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reistedl RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706-15.
16. Whiteside TL, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7: 704-10.
17. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamanstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interluekin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA 1993; 90: 2774-8.
18. Hunng K, Hayashi R, Lafond-Walker A, Lowebstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-68.
19. Segal BM, Glass DD, Shevach EM. Cutting edge: IL-10-producing CD4+ T cells mediated tumor rejection. J Immunol 2002; 168: 1-4.
20. Coombo HP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
21. Ma H-L, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perfolin but are independent of IFN-γ. J Immunol 2003; 171: 608-15.